Earnings results for Inhibrx (NASDAQ:INBX)
Inhibrx, Inc. is estimated to report earnings on 03/05/2021. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.5.
Analyst Opinion on Inhibrx (NASDAQ:INBX)
4 Wall Street analysts have issued ratings and price targets for Inhibrx in the last 12 months. Their average twelve-month price target is $34.67, predicting that the stock has a possible upside of 18.76%. The high price target for INBX is $44.00 and the low price target for INBX is $30.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Inhibrx has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $34.67, Inhibrx has a forecasted upside of 18.8% from its current price of $29.19. Inhibrx has received no research coverage in the past 90 days.
Dividend Strength: Inhibrx (NASDAQ:INBX)
Inhibrx does not currently pay a dividend. Inhibrx does not have a long track record of dividend growth.
Insiders buying/selling: Inhibrx (NASDAQ:INBX)
In the past three months, Inhibrx insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $440,300.00 in company stock. 36.63% of the stock of Inhibrx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Earnings and Valuation of Inhibrx (NASDAQ:INBX
Earnings for Inhibrx are expected to grow in the coming year, from ($2.56) to ($2.13) per share.
More latest stories: here